Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPD100PEGLi
- Development stage
- Preclinical
- Lead developer
- Cascade Prodrug
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPD100PEGLi is a research-stage PEGylated liposomal formulation of CPD100, a hypoxia-activated prodrug (HAP) of the microtubule inhibitor vinblastine. Developed by Cascade Prodrug, the formulation utilizes PEGylated liposomes to encapsulate the vinblastine N-oxide prodrug, aiming to enhance its pharmacokinetic profile and tumor accumulation through the enhanced permeability and retention (EPR) effect. CPD100 is designed to remain inactive in normal, oxygenated tissues but undergoes bioreductive activation to release potent vinblastine specifically within the hypoxic microenvironment of solid tumors. This dual-targeting approach, combining liposomal delivery with hypoxia-specific activation, is intended to maximize anti-tumor efficacy while minimizing the systemic toxicities typically associated with vinca alkaloids.
- Other names
- PEGylated liposomal CPD100PEGylated liposomal vinblastine N-oxide prodrug
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CPD100PEGLi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPD100PEGLi.